Recognition and Management of Treatment-Induced Cardiac Toxicity in Cancer Survivors

This information was originally presented at the NCCN 2017 Oncology Fellows Program: New Horizons in Quality Cancer Care™ held on March 26, 2017.

The purpose of this program is to educate future oncology practitioners about the application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other evidence-based treatment principles in the management of significant cancer types and supportive care issues.

Target Audience

These educational programs are designed to meet the educational needs of medical, surgical, and radiation oncology fellows.

Learning Objectives

Following this program, participants should be able to:

  • Recognize risk factors for the development of heart failure in cancer survivors
  • Summarize the recommendations regarding screening for and treatment of anthracycline-induced cardiotoxicity in the NCCN Guidelines for Survivorship
Additional information

This activity is supported by educational grants from: AstraZeneca; Pfizer; Prometheus Laboratories Inc.; supported by educational funding provided by Amgen; supported by an independent medical education grant from Bristol-Myers Squibb; and supported by an independent educational grant from TESARO. 

Course summary
Course opens: 
Course expires: 

Javid Moslehi, MD
Vanderbilt-Ingram Cancer Center


Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support.

The faculty listed below disclose the following relevant financial relationships:
Javid Moslehi, MD
Acceleron: Consulting Fees
ARIAD Pharmaceuticals, Inc.: Consulting Fees
Bristol-Myers Squibb Company: Consulting Fees
CardioOnc, LLC: Founder
Heat Biologics, Inc.: Consulting Fees
Incyte Corporation: Consulting Fees
Millennium Pharmaceuticals, Inc.: Consulting Fees
Novartis Pharmaceuticals Corporation: Consulting Fees
Pfizer Inc.: Consulting Fees
Pharmacyclics: Consulting Fees
Rgenix, Inc.:Consulting Fees
StemcentRx: Consulting Fees
Takeda Pharmaceuticals North America, Inc.: Consulting Fees
Verastem Inc.:Consulting Fees
Vertex Pharmaceuticals Incorporated: Consulting Fees

The activity planning staff listed below has no relevant financial interests to disclose:
Kimberly Bayer; Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until February 7, 2017); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until February 3, 2017)

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Deborah Freedman-Cass, PhD; Nicole McMillian, MS

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Continuing education credit and contact hours are not available for this learning activity.


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: